Decreased Excretion of Urinary Exosomal Aquaporin-2 in a Puromycin Aminonucleoside-Induced Nephrotic Syndrome Model
Autor: | Ayaha Kaito, Naruki Fujimoto, Masahiro Ikeda, Ahmed Abdeen, Hiroko Sonoda, Sayaka Oshikawa-Hori |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Male Nephrotic Syndrome medicine.medical_treatment aquaporin-2 030232 urology & nephrology Urine urologic and male genital diseases Exosomes lcsh:Chemistry 0302 clinical medicine lcsh:QH301-705.5 Spectroscopy Proteinuria nephrotoxicity General Medicine Computer Science Applications Aquaporin 2 medicine.symptom Injections Intraperitoneal medicine.medical_specialty puromycin aminonucleoside Urinary system Intraperitoneal injection Down-Regulation Catalysis Article Nephrotoxicity Inorganic Chemistry Excretion 03 medical and health sciences Internal medicine medicine Animals Physical and Theoretical Chemistry Molecular Biology business.industry urogenital system Organic Chemistry medicine.disease Rats Disease Models Animal 030104 developmental biology Endocrinology lcsh:Biology (General) lcsh:QD1-999 business Nephrotic syndrome urinary exosomes Biomarkers |
Zdroj: | International Journal of Molecular Sciences International Journal of Molecular Sciences, Vol 21, Iss 4288, p 4288 (2020) Volume 21 Issue 12 |
ISSN: | 1422-0067 |
Popis: | Urinary exosomes, small extracellular vesicles present in urine, are secreted from all types of renal epithelial cells. Aquaporin-2 (AQP2), a vasopressin-regulated water channel protein, is known to be selectively excreted into the urine through exosomes (UE-AQP2), and its renal expression is decreased in nephrotic syndrome. However, it is still unclear whether excretion of UE-AQP2 is altered in nephrotic syndrome. In this study, we examined the excretion of UE-AQP2 in an experimental rat model of nephrotic syndrome induced by the administration of puromycin aminonucleoside (PAN). Rats were assigned to two groups: a control group administered saline and a PAN group given a single intraperitoneal injection of PAN (125 mg/kg) at day 0. The experiment was continued for 8 days, and samples of urine, blood, and tissue were collected on days 2, 5, and 8. The blood and urine parameters revealed that PAN induced nephrotic syndrome on days 5 and 8, and decreases in the excretion of UE-AQP2 were detected on days 2 through 8 in the PAN group. Immunohistochemistry showed that the renal expression of AQP2 was decreased on days 5 and 8. The release of exosomal marker proteins into the urine through UEs was decreased on day 5 and increased on day 8. These data suggest that UE-AQP2 is decreased in PAN-induced nephrotic syndrome and that this reflects its renal expression in the marked proteinuria phase after PAN treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |